Evaluation and management of hematuria Flashcards
Characterization of gross hematuria depending on the phase and explain indication
- Initial–> urethral source 2. Terminal –> Trigone,neck prostate 3. Total hematuria –> Bladder and above
causes of pigmenturia mimicking GH:
- Endogenous sources (Bilirubin, myoglobin, porphyrins) 2. Food (Beets, rhubarb) 3. Drugs (phenazopyridine) 4. simple dehydration
AUA definition of microscopic hematuria
3 or more / HPF
causes of false positives for MH, cause of false negative
first void urine and post sexual activity might cause false positive Dilute urine (<308 osm) -> might cause false negative
The likelihood of identifying a malignancy has been found to be greater among patients with higher levels of MH _ RBC/HPF, GH, or risk factors for malignancy
>25 rbc/hpf
Common Risk Factors for Urinary Tract Malignancy in Patients With Microscopic Hematuria
Patients who develop hematuria who are taking anticoagulaton or antiplatelet medications should undergo _____.
patients who develop hematuria (microscopic or gross) who are taking anticoagulation or antiplatelet medications (e.g., warfarin, enoxaparin, heparin, aspirin, clopidogrel, nonsteroidal anti-inflammatory agents) should undergo a complete evaluation in the same manner as patients not taking such medications
In women, the ACOGAU society recommend/does not recommend evaluation for asymptomatic MH for patients that has never smoked aged 33-50 who have <25 hpc. What is the rate of Urinary tract for this malignancy for this patients
does not recomment, <0.5%
Blue light cystoscopy uses _____ or ____ instillation
AUA recommends for/against using blue-light cystoscopy for evaluation of MH
5-aminolevulinic acid ALA or Hexyl aminolevulinate (HAL)
Against
the imaging of choice by the AUA for evaluation of asymptomatic MH
Multiphasic ct urogram
36/F patient consulted for Asymptomatic MH,noted no infection, no menstruation,no urologic procedures, what is the next step for workup
Renal function testing, cystoscopy imaging CTU. COncurrent workup for proteinuria and red cell morphology to see if there is nephrological cause.
If negative for the following, the patient may follow-up at least one UA/Micro yearly for at least 2 years. If still with persistent MH, annual must be done. Repeat anatomic evaluation within 3-5 years if clinically indicated
patients presenting with GH in the absence of antecedent ___ or____ should be evaluated with a ____ examination, ___ and ____
patients presenting with GH in the absence of antecedent trauma or culture-documented UTI should be evaluated with a urine cytologic examination, cystoscopy, and upper tract imaging, preferably CT urogram.
_____________, a member of the ____ family, is the most common virus associated with hemorrhagic cystitis
BK virus, polyomavirus
treatment for viral hemorrhagic cystitis is:___
primarily supportive, with hydration, diuresis, and bladder irrigation, although case reports of success with antiviral therapy exist
Chemotherapeutic drugs that cause Hemorrhagic cystitis
Bladder toxicity results from renal excretion of the metabolite ___, which is produced by the liver and stimulates bladder mucosal sloughing and subsequent tissue edema/fibrosis
____, which binds to ___ and renders it inert, has been suggested for prophylaxis against cyclophosphamide-induced hemorrhagic cystitis
cyclophosphomide and iphosphamide
Bladder toxicity results from renal excretion of the metabolite acrolein, which is produced by the liver and stimulates bladder mucosal sloughing and subsequent tissue edema/fibrosis
2-Mercaptoethane sulfonate (mesna), which binds to acrolein and renders it inert, has been suggested for prophylaxis against cyclophosphamide-induced hemorrhagic cystitis